Get the Stockscreener App
0.65
0.08%
0.0005
AEON Biopharma Inc. stock is traded at $0.65, with a volume of 164.55K.
It is up +0.08% in the last 24 hours and up +15.33% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.6495
Open:
$0.63
24h Volume:
164.55K
Relative Volume:
0.83
Market Cap:
$25.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.56%
1M Performance:
+15.33%
6M Performance:
-48.82%
1Y Performance:
-88.41%
1-Day Range:
$0.58
$0.65
1-Week Range:
$0.58
$0.712
52-Week Range:
$0.5206
$17.17
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.65 | 25.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
Head to Head Survey: AEON Biopharma (AEON) & Its Peers - Defense World
AEON Biopharma (AEON) vs. Its Peers Critical Survey - Defense World
Comparing AEON Biopharma (AEON) & Its Competitors - Defense World
Migraine Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Amgen, Teva Pharma, Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories - Barchart
Blue Owl Capital Holdings LP Acquires New Stake in AEON Biopharm - GuruFocus.com
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma : Reports Third Quarter 2024 Financial Results and Provides Corporate Update Form 8 K - Marketscreener.com
AEON Biopharma Advances BOTOX Biosimilar Development, Secures FDA Meeting Milestone | AEON Stock News - StockTitan
Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer - GlobeNewswire
AEON Biopharma Inc. (AEON) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
AEON Biopharma Releases New Investor Presentation - TipRanks
AEON Biopharma stock earns buy rating, holds price target on FDA meeting - Investing.com
AEON Biopharma maps FDA path for Botox biosimilar - Investing.com
AEON receives positive outcome in FDA biosimilar advisory meeting - MSN
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting - The Manila Times
AEON Biopharma (AMEX:AEON) Stock Quotes, Forecast and News Summary - Benzinga
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Trading Day Triumph: AEON Biopharma Inc. (AEON) Ends at 0.83, a -12.12 Surge/Plunge - The Dwinnex
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - ForexTV.com
HC Wainwright Analysts Raise Earnings Estimates for AEON Biopharma, Inc. (NASDAQ:AEON) - Defense World
Vanguard Group Inc. Increases Position in AEON Biopharma, Inc. (NASDAQ:AEON) - Defense World
AEON Biopharma (NASDAQ:AEON) Given New $5.00 Price Target at HC Wainwright - Defense World
HC Wainwright Weighs in on AEON Biopharma, Inc.’s FY2028 Earnings (NASDAQ:AEON) - Defense World
H.C. Wainwright sees potential in AEON Biopharma stock despite funding uncertainties - Investing.com Canada
Midday Stock Roundup: Veritone Soars on NCAA Deal - Orange County Business Journal
AEON Stock Earnings: AEON Biopharma Beats EPS for Q2 2024 - InvestorPlace
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
AEON Biopharma : Corporate Presentation - Marketscreener.com
AEON Biopharma Inc. (AEON) Stock: From Low to High in 52 Weeks - The InvestChronicle
AEON Biopharma Releases New Corporate Presentation - TipRanks
Ratio Analysis: Unpacking AEON Biopharma Inc. (AEON)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
AEON Biopharma (NASDAQ:AEON) Shares Down 11.8% - MarketBeat
Was there any good news for AEON Biopharma Inc. (AEON) stock in the last session? - US Post News
AEON Biopharma (NASDAQ:AEON) Trading Down 11.8% - Defense World
The Psychology of AEON Biopharma Inc. Inc. (AEON) Price Performance: Understanding Market Sentiment - The InvestChronicle
Insider’s View: Deciphering AEON Biopharma Inc. (AEON)’s Financial Health Through Ratios - The Dwinnex
Midday Stock Roundup: loanDepot Rises on Investor Hopes for Fed - Orange County Business Journal
Views of Wall Street’s Leading Experts on AEON Biopharma Inc. - SETE News
How to interpret AEON Biopharma Inc. (AEON)’s stock chart patterns - US Post News
AEON Biopharma Inc. (AEON) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
AEON Biopharma Inc. Stock (AEON) Financials Data
There is no financial data for AEON Biopharma Inc. (AEON). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Cap:
|
Volume (24h):